Literature DB >> 27893888

Potential Neuroprotective Effects of an LSD1 Inhibitor in Retinal Ganglion Cells via p38 MAPK Activity.

Takayuki Tsutsumi1, Keiichiro Iwao1, Hideki Hayashi2, Tomoko Kirihara3, Takahiro Kawaji1, Toshihiro Inoue1, Shinjiro Hino4, Mitsuyoshi Nakao4, Hidenobu Tanihara1.   

Abstract

Purpose: The epigenetic mechanisms associated with ocular neurodegenerative diseases remain unclear. The present study aimed to determine the role of lysine-specific demethylase 1 (LSD1), which represses transcription by removing the methyl group from methylated lysine 4 of histone H3, in retinal ganglion cell (RGC) survival, and to investigate the details of the neuroprotective mechanism of tranylcypromine, a major LSD1 inhibitor.
Methods: The authors evaluated whether tranylcypromine contributes to neuronal survival following stress-induced damage using primary cultured rat RGCs and in vivo N-methyl-D-aspartate (NMDA)-induced excitotoxicity. Additionally, the molecules associated with tranylcypromine treatment were assessed by microarray and immunoblot analysis.
Results: Tranylcypromine significantly suppressed neuronal cell death following glutamate neurotoxicity and oxidative stress. Microarray and immunoblot analyses revealed that p38 mitogen-activated protein kinase (MAPK)γ was a key molecule involved in the neuroprotective mechanisms induced by tranylcypromine because the significant suppression of p38 MAPKγ by glutamate was reversed by tranylcypromine. Moreover, although pharmacologic inhibition of the phosphorylation of the total p38 MAPKs interfered with neuroprotective effects of tranylcypromine, the specific inhibition of p38 MAPKα and p38 MAPKβ did not influence RGC survival. This suggests that the non-p38 MAPKα/β isoforms have important roles in neuronal survival by tranylcypromine. Additionally, the intravitreal administration of tranylcypromine significantly saved RGC numbers in an in vivo glaucoma model employing NMDA-induced excitotoxicity. Conclusions: These findings indicate that tranylcypromine-induced transcriptional and epigenetic regulation modulated RGC survival via the promotion of p38 MAPKγ activity. Therefore, pharmacologic treatments that suppress LSD1 activity may be a novel therapeutic strategy that can be used to treat neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27893888     DOI: 10.1167/iovs.16-19494

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  6 in total

1.  Inhibition of TLR4 alleviates the inflammation and apoptosis of retinal ganglion cells in high glucose.

Authors:  Lili Hu; Hongxia Yang; Ming Ai; Shuanghong Jiang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-08-14       Impact factor: 3.117

Review 2.  Role of NAD+ and FAD in Ischemic Stroke Pathophysiology: An Epigenetic Nexus and Expanding Therapeutic Repertoire.

Authors:  Parimala Narne; Prakash Babu Phanithi
Journal:  Cell Mol Neurobiol       Date:  2022-09-30       Impact factor: 4.231

3.  GAP-43 Induces the Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells into Retinal Ganglial-Like Cells.

Authors:  Xiaoke Wang; Chi Ma; Lili Nie
Journal:  Comput Math Methods Med       Date:  2022-04-21       Impact factor: 2.809

Review 4.  Epigenetic Regulation of Optic Nerve Development, Protection, and Repair.

Authors:  Ajay Ashok; Sarita Pooranawattanakul; Wai Lydia Tai; Kin-Sang Cho; Tor P Utheim; Dean M Cestari; Dong Feng Chen
Journal:  Int J Mol Sci       Date:  2022-08-10       Impact factor: 6.208

5.  Targeting Polyamine Oxidase to Prevent Excitotoxicity-Induced Retinal Neurodegeneration.

Authors:  Prahalathan Pichavaram; Chithra Devi Palani; Chintan Patel; Zhimin Xu; Esraa Shosha; Abdelrahman Y Fouda; Ruth B Caldwell; Subhadra Priya Narayanan
Journal:  Front Neurosci       Date:  2019-01-10       Impact factor: 4.677

6.  Characterization of LSD1 Expression Within the Murine Eye.

Authors:  Salma Ferdous; Hans E Grossniklaus; Jeffrey H Boatright; John M Nickerson
Journal:  Invest Ophthalmol Vis Sci       Date:  2019-11-01       Impact factor: 4.799

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.